Monday 27th May 2024 |
Text too small? |
WELLINGTON, New Zealand - Chatham Rock Phosphate Limited (“CRP”) (TSXV: NZP, NZX: CRP , Frankfurt Borse: 3GRE) is very pleased to advise that Munich based Dr Georg Hochwimmer has today been appointed as a director. This is the logical next step in a close association with Dr Hochwimmer which now spans eight years since our first meeting at the PDAC conference in Toronto in 2016.
During that period Dr Hochwimmer has worked actively sourcing equity capital for Chatham from his networks in Europe, Canada and elsewhere and he is presently our largest shareholder in his own right.
Dr Hochwimmer operates General Research GmbH, a consulting company providing financial analysis, corporate finance and investor relations advice. General Research is particularly focused on emerging growth companies and Dr Hochwimmer has been a founding director of several technology start-ups.
His PhD qualification, connections and business experience are welcome additions to an already well-rounded Board and these attributes and his Europe location are particularly relevant to Chatham’s target markets in that region.
For further information please contact:
Chris Castle
President and Chief Executive Officer
Chatham Rock Phosphate Limited
64 21 55 81 85 or chris@crpl.co.nz
Statements about the Company’s future expectations and all other statements in this press release other than historical facts are “forward looking statements”. Such forward-looking statements are based on numerous assumptions, and involve known and unknown risks, uncertainties and other factors, including risks inherent in mineral exploration and development, which may cause the actual results, performance, or achievements of the Company to be materially different from any projected future results, performance, or achievements expressed or implied by such forward-looking statements.
Neither the Exchange, its Regulation Service Provider (as that term is defined under the policies of the Exchange), or New Zealand Exchange Limited has in any way passed upon the merits of the above descried transaction and has neither approved nor disapproved of the contents of this press release.
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors